
Optum Insight is owned by UnitedHealth Group, Inc. (NYSE: UNH), a publicly traded American healthcare company headquartered in Minnetonka, Minnesota. Optum Insight is UnitedHealth Group's healthcare data analytics, technology, and consulting division. It acquired Change Healthcare for approximately $13 billion in October 2022. Optum Insight generated revenues of $19.4 billion in fiscal year 2025, up 4% from 2024. The division completed its acquisition of Alegeus on July 2, 2026, expanding its consumer-directed healthcare account capabilities. UnitedHealth Group is led by CEO Stephen Hemsley, who returned to the role in May 2025.
Parent Company
Founded
2011
Status
Publicly Traded
Headquarters
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Optum Insight | UnitedHealth Group | Wholly owned |
Optum Insight's origins trace to UnitedHealth Group's formation of Optum as a consolidated health services platform in 2011. The division was established to provide healthcare data analytics, technology, and consulting services to health plans, hospitals, physician practices, employers, and government agencies. UnitedHealth Group's healthcare data assets, accumulated through its UnitedHealthcare insurance operations, provided a foundation for building analytics capabilities.
Optum Insight expanded through a series of acquisitions throughout the 2010s, acquiring healthcare technology and analytics companies to strengthen its capabilities. Key acquisitions included Ingenix (a healthcare data and analytics company that was rebranded as Optum Insight), The Advisory Board Company's healthcare consulting business, and numerous smaller analytics and technology firms.
The most significant development in Optum Insight's history was the January 2021 announcement of UnitedHealth Group's agreement to acquire Change Healthcare for approximately $13 billion. Change Healthcare was one of the largest healthcare technology companies in the United States, processing approximately 15 billion healthcare transactions annually through its claims processing, payment, and data analytics platforms. The acquisition was intended to combine Change Healthcare's transaction processing capabilities with Optum Insight's analytics and consulting services.
The Change Healthcare acquisition faced regulatory opposition. The U.S. Department of Justice filed an antitrust lawsuit in February 2022, arguing that the combination would give UnitedHealth Group access to sensitive data from rival health insurers that used Change Healthcare's transaction processing services. The DOJ argued that this data access would allow UnitedHealth Group to disadvantage competitors in the health insurance market. A federal judge dismissed the DOJ's lawsuit in September 2022, ruling that the government had not demonstrated that the acquisition would substantially lessen competition. The merger completed in October 2022.
Following the Change Healthcare acquisition, Optum Insight's revenues increased substantially. The division saw a 35% revenue increase year over year, reflecting the addition of Change Healthcare's transaction processing revenues to Optum Insight's existing analytics and consulting revenues.
On February 21, 2024, UnitedHealth Group identified that a malicious actor had gained unauthorized access to Change Healthcare's information technology systems. The ransomware attack, attributed to the ALPHV/BlackCat ransomware group, disrupted Change Healthcare's claims processing and payment systems for weeks, affecting thousands of hospitals, physician practices, pharmacies, and other healthcare providers across the United States. The attack was described as one of the largest healthcare cyberattacks in U.S. history. UnitedHealth Group paid a ransom and spent hundreds of millions of dollars on remediation and support for affected healthcare providers.
Optum Insight's 2024 revenues of $18.8 billion were down approximately 1% from 2023, reflecting the disruption caused by the ransomware attack. In 2025, the division recovered. Full year 2025 revenues reached $19.4 billion, up 4% or $660 million year over year. Earnings from operations were $2.6 billion, compared to $3.1 billion in 2024. Adjusted earnings from operations were $3.7 billion, down from $4.4 billion in 2024, as the division invested in new product launches and continued technology development.
In May 2025, CEO Andrew Witty stepped down and Stephen Hemsley returned as CEO. Hemsley initiated a broad set of reforms focused on affordability, transparency, and operational discipline across UnitedHealth Group. Under his leadership, Optum Insight continued to bring AI-enabled products to market, including autonomous coding and digital prior authorization tools.
On January 1, 2026, UnitedHealth Group realigned Optum Financial, including Optum Bank, from Optum Health into Optum Insight. This realignment expanded the division's consumer-directed healthcare account capabilities. In Q1 2026, Optum Insight reported revenues of $5.1 billion. In Q2 2026, revenues grew to $5.4 billion with earnings from operations of $1.4 billion, up from $1.2 billion in Q2 2025. On July 2, 2026, the division completed its acquisition of Alegeus Technologies, further expanding its consumer-directed healthcare account platform.
UnitedHealth Group's 2026 outlook projects Optum Insight revenues exceeding $21 billion with operating earnings greater than $4,750 million and an operating margin of approximately 22.6%.
UnitedHealth Group operates through two primary platforms that work together to deliver comprehensive healthcare solutions: UnitedHealthcare and Optum. This integrated business model enables the company to serve the entire healthcare continuum, from insurance coverage to direct healthcare delivery and technology services, creating synergies that enhance both quality and efficiency.
UnitedHealthcare represents the company's health insurance and benefits division, providing coverage to individuals, employers, and government-sponsored programs including Medicare and Medicaid. In 2025, UnitedHealthcare served 49.8 million consumers and achieved revenues of $344.9 billion, representing 16% growth year-over-year. The division operates through multiple business segments including individual and family plans, employer-sponsored coverage, Medicare Advantage plans, and Medicaid managed care programs.
UnitedHealthcare's success stems from its extensive provider networks, innovative benefit designs, and focus on value-based care models. The company has developed sophisticated approaches to care coordination, preventive health programs, and chronic disease management that improve health outcomes while managing costs effectively. UnitedHealthcare's market leadership position enables it to negotiate favorable terms with healthcare providers and develop innovative insurance products that meet evolving consumer needs.
Optum delivers comprehensive healthcare services and technology solutions through three main segments that support the entire healthcare ecosystem:
Optum Health provides direct patient care and health services, operating clinics, surgical centers, and home health services. The segment employs healthcare professionals including physicians, nurses, and care coordinators who deliver integrated care to patients across various settings. Optum Health focuses on value-based care models that align financial incentives with health outcomes, creating more efficient and effective healthcare delivery systems.
Optum Insight offers data analytics, consulting, and technology services to healthcare organizations, payers, and life sciences companies. The segment leverages UnitedHealth Group's vast healthcare data assets to provide insights that improve clinical outcomes, reduce costs, and enhance operational efficiency. Optum Insight's services include population health management, revenue cycle optimization, and healthcare technology implementation.
Optum Rx manages pharmacy benefits for millions of people, negotiating with pharmaceutical manufacturers and managing prescription drug programs. In 2025, Optum Rx achieved 15% revenue growth, demonstrating strong performance in the pharmacy benefits management market. The segment combines purchasing power with clinical expertise to optimize medication therapy, improve adherence, and manage drug costs effectively.
UnitedHealth Group's integrated business model creates significant competitive advantages. The company's ability to combine insurance coverage with direct healthcare delivery enables better care coordination, improved health outcomes, and more efficient resource utilization. This integration also provides valuable data insights that inform product development, care management programs, and operational improvements.
In 2025, UnitedHealth Group demonstrated exceptional financial performance with consolidated revenues of $447.6 billion, representing 12% growth year-over-year. The company's adjusted earnings from operations reached $21.7 billion, reflecting strong operational execution despite challenges including cyberattack-related costs and business restructuring charges.
In Q2 2026, UnitedHealth Group reported revenues of $112.0 billion and earnings from operations of $8.0 billion, with net margin of 4.9%. Cash flows from operations were $11.1 billion, or 1.9 times net income. UnitedHealthcare served 48.5 million consumers (down from 49.8 million in 2025) and reported Q2 2026 revenues of $86.0 billion with earnings of $3.9 billion. Optum supported over 120 million consumers and generated Q2 2026 revenues of $65.7 billion with earnings of $4.0 billion, representing 160 basis points of margin expansion year over year.
The company's financial metrics demonstrate operational efficiency and strong cash generation. UnitedHealth Group achieved cash flows from operations of $19.7 billion in 2025, representing 1.5 times net income. The company maintains a debt-to-capital ratio of 41.2% (as of June 30, 2026) and targets a long-term ratio of 40.0%, reflecting prudent financial management.
UnitedHealth Group employs approximately 440,000 people worldwide, making it one of the largest employers in the healthcare industry. The company's workforce includes healthcare professionals, technology specialists, data analysts, and business professionals who support the company's integrated healthcare delivery model.
Looking toward 2026, UnitedHealth Group initially established revenue guidance greater than $439.0 billion (a 2% decline reflecting divestitures and membership reduction) and adjusted earnings outlook greater than $17.75 per share. After strong Q2 2026 results, the company raised its full-year 2026 guidance to adjusted net earnings of $19.50 to $20.00 per share, with earnings from operations greater than $25.2 billion. The company expects operating earnings from UnitedHealthcare to exceed $12 billion, Optum Health to exceed $2.2 billion, Optum Insight to exceed $4.9 billion, and Optum Rx to exceed $6.25 billion. Cash flows from operations are expected to be approximately $24 billion, with share repurchases of at least $5 billion.
Optum Insight operates under UnitedHealth Group's corporate sustainability framework. As a healthcare data analytics and technology provider, the division's primary sustainability concerns center on data privacy, cybersecurity, and responsible AI development.
Data Privacy and Security: Optum Insight maintains data privacy and security standards for handling healthcare data, implementing encryption, access controls, and privacy-by-design principles. The division's data governance programs ensure compliance with HIPAA, GDPR, and other healthcare data protection regulations. Following the February 2024 ransomware attack on Change Healthcare, the division has significantly enhanced its cybersecurity infrastructure, implementing advanced threat detection systems, multi-factor authentication requirements, and comprehensive employee training programs.
Cybersecurity Investments: The 2024 ransomware attack prompted substantial cybersecurity investments. UnitedHealth Group reported $799 million in direct response costs related to the cyberattack in 2025. The company has implemented partnerships with leading security firms, regular security assessments, and more resilient healthcare payment processing systems.
Ethical AI Development: Optum Insight has developed AI-enabled products including autonomous coding and digital prior authorization tools. The division's AI ethics framework addresses transparency in algorithmic decision-making, bias detection and mitigation, and human oversight of AI systems that impact patient care or healthcare operations.
Environmental Initiatives: UnitedHealth Group has committed to reducing its environmental footprint, including carbon emission reduction targets across its operations. Optum Insight's data center operations contribute to these goals through energy-efficient computing infrastructure and renewable energy sourcing where available.
Optum Insight's AI-enabled products, including autonomous coding and digital prior authorization tools, have received attention in the healthcare technology industry. The division's launch of these AI products in 2025 and 2026 has been noted by healthcare IT publications as a meaningful step toward reducing administrative burden in healthcare operations.
The successful integration of Change Healthcare following the $13 billion acquisition has been noted by healthcare industry analysts as a complex technology integration achievement. The division's ability to maintain service continuity during the transition while realizing synergies from the combination has been acknowledged in healthcare technology M&A analysis.
Optum Insight's cybersecurity response and recovery efforts following the February 2024 ransomware attack have been discussed at healthcare industry conferences and in cybersecurity publications. The company's implementation of enhanced security measures and financial support for affected healthcare providers has been noted by healthcare industry groups.
Optum Insight has faced several significant challenges and controversies, most notably the February 2024 ransomware attack on Change Healthcare.
February 2024 Ransomware Attack: The most significant controversy in Optum Insight's history occurred in February 2024 when a ransomware attack on Change Healthcare disrupted healthcare payment processing across the United States. The attack, attributed to the ALPHV/BlackCat ransomware group, affected thousands of hospitals, physician practices, pharmacies, and other healthcare providers. UnitedHealth Group paid a ransom and spent hundreds of millions of dollars on remediation and support for affected providers. In 2025, the company reported $799 million in direct response costs related to the cyberattack.
Change Healthcare Acquisition Antitrust Lawsuit: The U.S. Department of Justice filed an antitrust lawsuit to block the $13 billion acquisition of Change Healthcare, arguing that the combination would give UnitedHealth Group access to sensitive competitive data from rival health insurers. A federal judge dismissed the DOJ's lawsuit in September 2022, but the acquisition attracted significant attention regarding healthcare market concentration.
Data Privacy and Security Concerns: As a major healthcare data processor handling sensitive patient information and claims data, Optum Insight faces ongoing scrutiny regarding data privacy and security practices. The company's role in processing approximately 15 billion healthcare transactions annually creates significant data protection responsibilities.
Market Dominance and Competition Issues: Optum Insight's dominant position in healthcare claims processing and data analytics has raised concerns about reduced competition in healthcare technology markets. Smaller healthcare IT companies have struggled to compete with Optum Insight's scale and resources.
Algorithm Transparency Concerns: Optum Insight's use of AI and machine learning algorithms in healthcare decision-making has faced criticism regarding transparency and potential bias. Some healthcare providers and patient advocates have questioned whether the company's algorithms are sufficiently transparent and whether they may create unfair advantages for UnitedHealth Group's insurance operations.
Leadership Transition: In May 2025, CEO Andrew Witty stepped down and Stephen Hemsley returned as CEO. The transition occurred amid government investigations, higher than expected medical costs, and public scrutiny following the December 2024 murder of UnitedHealthcare CEO Brian Thompson. UnitedHealth Group also withdrew its 2025 financial outlook at the time of the leadership change.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Unitedhealth Group | USA | 2013 | Mass market | United states | All Genders | |
| Unitedhealth Group | USA | 2011 | Mass market | Global | All-ages |
Healthcare PharmaceuticalsOwned by UnitedHealth Group
Healthcare technology company providing claims processing and payment solutions, owned by UnitedHealth Group.
Healthcare PharmaceuticalsOwned by UnitedHealth Group
UnitedHealth Group's healthcare services platform formed in 2011, operating through Optum Health, Optum Insight, and Optum Rx to generate $270.6 billion in combined 2025 revenues and supporting more than 123 million consumers.
Market Positioning: Optum Insight competes with 2 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by UnitedHealth Group, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by GE HealthCare Technologies Inc.
Independent publicly traded healthcare technology company spun off from General Electric in January 2023, providing medical imaging, diagnostics, and healthcare IT solutions globally.
GE HealthCare operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Pfizer Inc.
American multinational pharmaceutical corporation developing and manufacturing medicines, vaccines, and consumer healthcare products, one of the world's largest pharmaceutical companies.
Pfizer operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Koninklijke Philips N.V.
Health technology brand owned by Koninklijke Philips N.V., a publicly traded Dutch company listed on Euronext Amsterdam (PHIA). Covers medical imaging, patient monitoring, and personal health products.
Philips operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
Tirosint is privately owned, unlike Optum Insight which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Alcon Inc.
Independent publicly traded global eye care company headquartered in Geneva, Switzerland, specializing in surgical equipment, contact lenses, and ophthalmic products. Spun off from Novartis in April 2019.
Alcon operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Herbalife Ltd.
Global nutrition and weight-management brand owned by Herbalife Ltd. and sold through independent distributors in more than 90 markets.
Herbalife operates independently without a large parent corporation.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.

Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.